Ana Clara P. Azevedo‐Pouly

Researcher

UAMS primary NCTR

Also affiliated: Arkansas Children's Hospital (2021–2025); Children’s Institute (2022); United States Food and Drug Administration (2022); University of Utah (2017); University of Florida (2022); Arkansas Children's Nutrition Center (2025); The Ohio State University (2011–2017); The University of Texas Southwestern Medical Center (2016–2023)

Faculty Researcher

13 h-index 35 pubs 776 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Ana Clara P. Azevedo‐Pouly's research focuses on understanding the molecular mechanisms underlying pancreatic cancer and immune cell function. Her work investigates the role of DNA-activated protein kinase catalytic subunit (DNA-PKcs) in regulating gene expression and stabilizing transcription factors such as Egr1, particularly in immune cells like T cells. She has also explored the potential of pharmacological interventions, including the development of novel DNA-PKcs inhibitors like DA-143, to modulate immune cell activity and cytotoxicity. Additionally, her research extends to studying the cellular processes involved in pancreatic acinar cell metaplasia and oncogenic transformation, examining key transcriptional effectors that influence these phenotypes. Azevedo‐Pouly has also investigated the cardiotoxic effects of doxorubicin in mice, exploring the involvement of the apelin-APJ pathway. Her collaborations include work with Randall R Rainwater, Brian Koss, Lauren Elizabeth Appell, and Melanie Barker at the University of Arkansas for Medical Sciences, with whom she has co-authored multiple publications.

Metrics

h-index: 13
Publications: 35
Citations: 776

Selected Publications

DNA-PKcs Controls the Cytotoxic T-Cell Response to Cancer and Transplant Allograft Through Regulating LAT-Dependent Signaling (2025)

SSRN Electronic Journal DOI OpenAlex
DNA-PKcs governs LAT-dependent signaling in CD4 + and CD8 + T cells (2025)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
The use of DNAPK inhibitors increases the efficacy of Lentiviral vectors and decreases off-target effects. (2024)

The Journal of Immunology DOI OpenAlex
Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)

Scientific Reports 3 citations DOI OpenAlex
Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp>+ helper and <scp>CD8</scp>+ effector T cells (2023)

Immunology and Cell Biology 7 citations DOI OpenAlex
DNA-PKcs is required for the activation and cytotoxicity of CD8+ effector T cells (2022)

The Journal of Immunology DOI OpenAlex
Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice (2022)

Journal of Applied Toxicology 7 citations DOI OpenAlex
Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia (2022)

Cell Death Discovery 22 citations DOI OpenAlex
Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 + helper and CD8 + effector T cells (2022)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells (2021)

Journal of Biological Chemistry 22 citations DOI OpenAlex
DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells (2021)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics (2020)

Scientific Reports 3 citations DOI OpenAlex
Knockout of Acinar Enriched microRNAs in Mice Promote Duct Formation But Not Pancreatic Cancer (2019)

Scientific Reports 19 citations DOI OpenAlex